Chronic Obstructive Pulmonary Disease Market Global Forecast Report by Types Treatment Types Distribution Channels Countries and Company Analysis, 2024-2032

Chronic Obstructive Pulmonary Disease (COPD) Market Analysis

The Global Chronic Obstructive Pulmonary Disease Market has been valued at US$ 13.25 in 2023, it is estimated that the market worth's US$ 17. 22 billion by 2032 and the market is growing at the CAGR of 2. 96% from 2024-2032. Factors contributing to this expansion include:

• Increase in cigarette use by the youths.
• This has served to create the awareness of the relative benefits of consuming generic drugs to the population.
• Globalization, increase in literacy levels, healthcare reforms and third world countries' policies in encouraging and spending on health care.

COPD Market Overview

Chronic Obstructive Pulmonary Disease (COPD) is a permanent condition that causes limitation in breathing and in respiratory activities. It primarily encompasses two conditions: Such conditions as chronic bronchitis, and emphysema. COPD is usually instigated by long-standing exposure to poisonous dusts or gases, which are frequently inhaled through tobacco smoking. The disease also causes irritations and changes in the structure of the bronchial tubes and the lungs' tissues, which cause the difficulty in breathing, coughing and the production of excessive amounts of mucus.

The term 'uses' is not so directly applicable to COPD, as the latter is a disease which impacts the diagnosis and treatment, rather than an instrument which facilitates it. Such understanding forms the basis for management and all treatment regimens that are aimed at improved health. Management of COPD includes smoking cessation, long acting bronchodilators, inhaled corticosteroids, and pulmonary rehabilitation once the diagnosis has been made. Moreover, COPD offers a great model to explore lung inflammation, tissue alterations, and the impact of environmental agents on respiratory diseases as well as to make insights into the overall pulmonary medicine as well as public health efforts.

Growth Factors in the Chronic Obstructive Pulmonary Disease (COPD) Industry

Rising Global Prevalence of COPD:

The rise in the cases of COPD globally provides a key stimulant for the development of the industry. Some of the causes for this increase are population aging, high smoking prevalence in many areas of the world, and gradually increasing air pollution, especially in the developing countries. Increasingly, people are getting to know about COPD thus seek diagnosis hence many more patients will need to be attended to and treated. The World Health Organisation has predicted that COPD is likely to rise from being the fourth leading cause of death to the third by the year 2030. This increasing burden of disease has resulted to increased need for COPD special health care services, drugs and equipment. Thus, the pharma companies, the manufacturers of medical devices, and patients' care organizations increase their COPD portfolio, which drives the overall industry development and merges new approaches to COPD management.

Advancements in Diagnostic Technologies and Treatments:

Development of technological advancement is one of the key factors enhancing the growth of the COPD diagnosis and treatment industry. Enhancement in spirometry gadgets, portable pulmonary function, and imaging work up and features help to improve both early diagnosis and accuracy of COPD. In the treatment area, the identification of new bronchodilators, combination drugs, and targeted biological therapies is adding to the armoury of remedies for COPD patients. Advancements in drug delivery systems like smart inhalers which have monitoring features increase the chances of taking medication properly and increase their effectiveness. Also, as for the future, new prospective areas of COPD treatment include regenerative medicine and gene therapy. Such innovations have enhanced the quality of COPD treatment and opened new business prospects for companies dealing with the COPD care hence investing in such structures in the industry.

Increasing Focus on Personalized Medicine and Digital Health:

Current trends in the COPD industry reveal that the use of personalized medicine and digital health technologies is leading to growth in the industry. It is clear that genomics and biomarker research is helping several therapies to be tailored according to local characters and disease types. This approach results in the generation of targeted treatments and identification of diagnostic methods in the COPD market, resulting in expansion in types of products and services. At the same time, the use of digital health solutions such as RMP, mHealth, and predictive analytics helps COPD's management change. These technologies can thus help monitor ailments, prevent their development and, treat patients individually. The union of services that allow accommodation of individualized genomics or pharmacogenomics as well as services that back up the evolution of digital health is proving to be the gold mine of the traditional healthcare and technology investors regarding COPD industry.

Asia Chronic Obstructive Pulmonary Disease Market Overview

The market for Chronic Obstructive Pulmonary Disease (COPD) in Asia is currently rapidly increasing for several reasons. Population demographics and growth, coming together with increased rates of urbanization, and air pollution rates are also on the rise adding to the increased prevalence of COPD in the region. These are especially obvious since high-smoking countries such as China or India witness a consistent increase in COPD prevalence and as much as 90% of people in these nations suffer from inadequate air quality.

This market is known for rising concern, enhanced diagnostic profile, and enhanced access to treatment. National and regional healthcare bodies are planning and emplacing COPD care strategies and tobacco control campaigns. The sector is experiencing development of new forms of COPD therapies as well as conventional ones that include long-acting bronchodilators and combination therapies.

Despite these successes, the issues like late diagnosis, even in some rural settings, and inability to afford treatment remains a challenge. Nevertheless, the Asian COPD market is predicted to remain on the upgrade due to increase in technological developments in diagnosis and treatment techniques coupled with increase in expenditure to healthcare and an ageing population who are prone to COPD diseases.

Chronic Obstructive Pulmonary Disease Market Company Overview

The Global Chronic Obstructive Pulmonary Disease (COPD) Market is steered by industry leaders who have demonstrated their commitment and expertise. These leaders, including AstraZeneca, Pfizer Inc., GlaxoSmithKline plc, Novartis AG, Astellas Pharma Inc., Abbott Laboratories, Boehringer Ingelheim International GmbH, and Almirall, play a crucial role in shaping the market's future.

Chronic Obstructive Pulmonary Disease (COPD) Market News

In April 2024, A report on the results of the Phase 2a COURSE trial for TEZSPIRE (tezepelumab-ekko) in patients with chronic obstructive pulmonary disease was issued by Amgen. Tezelumab was found to statistically lower the annualized rate of moderate-to-severe COPD exacerbations by 17%.

In March 2024, in head-to-head research using a human tissue model of chronic obstructive pulmonary disease, ASLAN Pharmaceuticals Ltd. reported new, encouraging translational evidence that supports eblasakimab's potential as a biologic therapy for COPD. The study pitted eblasakimab against dupilumab.

In February 2024, Regeneron Pharmaceuticals, Inc. and Sanofi declared that the supplemental Biologics License Application (sBLA) for Dupixent (dupilumab) in a sixth potential indication as an add-on maintenance treatment in specific adult patients with uncontrolled chronic obstructive pulmonary disease had been accepted for Priority Review by the US FDA.

In September 2024, Verona Pharma plc said that the company's New Drug Application (NDA) for ensifentrine, which seeks clearance for the maintenance treatment of patients with chronic obstructive pulmonary disease, has been authorized by the US Food and Drug Administration (FDA).

Types - Market breakup in 2 viewpoints:

1. Chronic Bronchitis

2. Emphysema

Treatment Types - Market breakup in 4 viewpoints:

1. Drugs

2. Oxygen Therapy

3. Surgery

4. Others

Distribution Channel - Market breakup in 3 viewpoints:

1. Hospital Pharmacies

2. Retail Pharmacies

3. Online Pharmacies

Country - Market breakup in 25 viewpoints:

North America

United States

Canada

Europe

France

Germany

Italy

Spain

United Kingdom

Belgium

the Netherlands

Turkey

Asia Pacific

China

Japan

India

Australia

South Korea

Thailand

Malaysia

Indonesia

New Zealand

Latin America

Brazil

Mexico

Argentina

Middle East & Africa

South Africa

Saudi Arabia

United Arab Emirates

All the Key players have been covered from 4 Viewpoints:

• Overviews
• Recent Developments & Strategies
• Product Portfolio & Product Launch in Last 1 Year
• Revenue

Company Analysis:

1. AstraZeneca

2. Pfizer, Inc.

3. GlaxoSmithKline plc.

4. Novartis AG

5. Astellas Pharma Inc.

6. Abbott Laboratories

7. Boehringer Ingelheim International GmbH

8. Almirall